IO Biotech, Inc. (IOBT)
NASDAQ: IOBT · Real-Time Price · USD
0.3400
-0.0205 (-5.69%)
At close: Feb 20, 2026, 4:00 PM EST
0.3350
-0.0050 (-1.47%)
After-hours: Feb 20, 2026, 7:59 PM EST
IO Biotech Employees
IO Biotech had 78 employees as of June 30, 2025. The number of employees increased by 4 or 5.41% compared to the same quarter last year.
Employees
78
Change
4
Growth
5.41%
Revenue / Employee
n/a
Profits / Employee
-$1,132,679
Market Cap
24.46M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 78 | 4 | 5.41% |
| Mar 31, 2025 | 79 | 9 | 12.86% |
| Dec 31, 2024 | 80 | 12 | 17.65% |
| Sep 30, 2024 | 78 | 10 | 14.71% |
| Jun 30, 2024 | 74 | - | - |
| Mar 31, 2024 | 70 | 13 | 22.81% |
| Dec 31, 2023 | 68 | 11 | 19.30% |
| Dec 31, 2022 | 57 | 25 | 78.13% |
| Dec 31, 2021 | 32 | 21 | 190.91% |
| Sep 30, 2021 | 19 | 8 | 72.73% |
| Jun 30, 2021 | 19 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Barinthus Biotherapeutics | 105 |
| IGC Pharma | 70 |
| Boundless Bio | 64 |
| Cue Biopharma | 41 |
| Senti Biosciences | 34 |
| Daré Bioscience | 23 |
| Skye Bioscience | 16 |
| Genenta Science | 13 |
IOBT News
- 23 days ago - IO Biotech Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - IO Biotech Announces Exploration of Strategic Alternatives - GlobeNewsWire
- 2 months ago - IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications - GlobeNewsWire
- 3 months ago - IO Biotech Announces Participation in Upcoming December Investor Conferences - GlobeNewsWire
- 3 months ago - IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewsWire
- 3 months ago - IO Biotech Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - GlobeNewsWire
- 4 months ago - IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025 - GlobeNewsWire